Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

RZLT
Rezolute, Inc. Common Stock (NV)
stock NASDAQ

Market Open
May 9, 2025 9:54:22 AM EDT
3.77USD+1.210%(+0.05)41,809
3.75Bid   3.78Ask   0.03Spread
Pre-market
May 8, 2025 9:17:30 AM EDT
3.70USD+2.496%(+0.09)0
After-hours
May 8, 2025 4:00:30 PM EDT
3.72USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Nov 29, 2021
08:16AM EST  Canaccord Genuity Maintains Buy on Rezolute, Lowers Price Target to $17   Benzinga
Nov 15, 2021
11:05AM EST  JMP Securities Maintains Market Outperform on Rezolute, Lowers Price Target to $18   Benzinga
Nov 12, 2021
04:05PM EST  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first quarter of fiscal 2022 ended September 30, 2021.   GlobeNewswire Inc
Oct 13, 2021
01:38PM EDT  Rezolute Prices ~6M Share Common Stock Offering At $6.50/Share   Benzinga
08:31AM EDT  Rezolute Reports Pricing Of Public Offering Of 6.03 Mln Shares At $6.50/Shr   RTTNews
08:11AM EDT  Rezolute Announces Pricing of Public Offering of $55 million of   GlobeNewswire Inc
Oct 12, 2021
04:06PM EDT  Rezolute Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants, And A Concurrent Registered Direct Offering; No terms Disclosed   Benzinga
04:05PM EDT  Rezolute Announces Proposed Public Offering of Common Stock and   GlobeNewswire Inc
Sep 22, 2021
04:06PM EDT  Rezolute Presents Results From Two-Week Natural History Study In Congenital Hyperinsulinism Patients On Standard Of Care Therapies At ESPE 2021   Benzinga
04:05PM EDT  Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism   GlobeNewswire Inc
Sep 15, 2021
04:57PM EDT  Rezolute Q4 EPS $(0.78)   Benzinga
04:56PM EDT  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quarter and fiscal full year ended June 30, 2021.   GlobeNewswire Inc
Sep 9, 2021
04:05PM EDT  Rezolute Announces Initiation of Dosing in the Second Cohort of   GlobeNewswire Inc
Sep 8, 2021
11:26AM EDT  Roth Capital Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $21   Benzinga
Sep 7, 2021
04:05PM EDT  Rezolute, Inc.(Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.   GlobeNewswire Inc
Aug 10, 2021
07:12AM EDT  Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute's Oral PKI for Treatment of DME   Benzinga
07:00AM EDT  Rezolute Announces Initiation of Multiple-Ascending Dose Study of   GlobeNewswire Inc
Aug 4, 2021
06:08AM EDT  Rezolute Inc On August 2, Entered Purchase Agreement With Lincoln Park Capital Fund; Under Agreement, Co May Sell To Lincoln Park Up To $20M Of Shares Of Its Common Stock   Benzinga
Aug 3, 2021
07:00AM EDT  Rezolute, Inc.(Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.   GlobeNewswire Inc
Jun 28, 2021
07:00AM EDT  Rezolute, Inc.(Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28.   GlobeNewswire Inc
May 27, 2021
02:38PM EDT  Mid-Afternoon Market Update: Dow Surges Over 100 Points; NextGen Healthcare Shares Plunge   Benzinga
12:17PM EDT  Mid-Day Market Update: Anaplan Drops After Q1 Earnings; Vertex Energy Shares Surge   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Mostly Higher; Dollar Tree Profit Tops Estimates   Benzinga
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021   Benzinga
07:00AM EDT  Rezolute, Inc.(Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.   GlobeNewswire Inc
06:25AM EDT  Oppenheimer Initiates Coverage On Rezolute with Outperform Rating, Announces Price Target of $25   Benzinga
May 25, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021   Benzinga
06:11AM EDT  HC Wainwright & Co. Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $21   Benzinga
May 20, 2021
07:00AM EDT  Rezolute Expands Leadership Team with the Appointment of Davelyn   GlobeNewswire Inc
May 18, 2021
07:00AM EDT  Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen,   GlobeNewswire Inc
May 17, 2021
04:17PM EDT  Rezolute Q3 EPS $(0.44) Up From $(0.86) YoY   Benzinga
04:05PM EDT  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fiscal third quarter ended March 31, 2021.   GlobeNewswire Inc
07:00AM EDT  Rezolute, Inc.(Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit. The presentation will be available on-demand starting at 8:00 AM ET on Friday, May 21, 2021.   GlobeNewswire Inc
May 12, 2021
10:21AM EDT  Canaccord Genuity Maintains Buy on Rezolute, Lowers Price Target to $30   Benzinga
May 4, 2021
12:33PM EDT  Rezolute's Plasma Kallikrein Inhibitor Shows Encouraging Action In Diabetic Macular Edema Study   Benzinga
08:21AM EDT  Rezolute Says RZ402 Study Results Demonstrate Potential For Once Daily Dosing Of An Oral Plasma Kallikrein Inhibitor For Diabetic Macular Edema   Benzinga
08:00AM EDT  Rezolute Announces Positive RZ402 Study Results Demonstrating   GlobeNewswire Inc
Apr 19, 2021
08:07AM EDT  Rezolute Announces $30M Debt Financing Agreement with SLR Capital Partners   Benzinga
08:00AM EDT  Rezolute, Inc. (Rezolute or the Company) (Nasdaq: RZLT), a clinical stage biopharmaceutical company dedicated to advancing targeted therapies for rare and metabolic diseases with serious unmet needs, today announced that it has entered into a $30 million debt financing agreement with investment affiliates managed by SLR Capital Partners (SLR).   GlobeNewswire Inc
Mar 22, 2021
08:12AM EDT  Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021; Co. Reports 'The study objective was met, with a clinically significant improvement in hypoglycemia by more than 50%, translating to near normalization of average glucose levels.'   Benzinga
08:12AM EDT  Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021; Co. Reports 'The study objective was met, with a clinically significant improvement in hypoglycemia by more than 50%, translating to near normalization of average glucose le   Benzinga
08:00AM EDT  Rezolute Presents Data on RZ358 in Post-Gastric Bypass   GlobeNewswire Inc
Mar 8, 2021
08:46AM EST  Rezolute, Inc. (Nasdaq: RZLT), today announced the appointments of Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA to its Board of Directors.   GlobeNewswire Inc
Mar 2, 2021
05:17PM EST  Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Companys CEO and Founder, will be presenting at the following upcoming investor conferences:   GlobeNewswire Inc
Feb 10, 2021
04:13PM EST  Rezolute Q2 EPS $(0.88) Up From $(1.14) YoY   Benzinga
04:05PM EST  Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.   GlobeNewswire Inc
Jan 12, 2021
08:35AM EST  Rezolute Announces Initiation Of Phase 1 Study Of RZ402, An Oral Plasma Kallikrein Inhibitor For Treatment Of Diabetic Macular Edema   Benzinga
08:30AM EST  RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME   GlobeNewswire Inc
Dec 28, 2020
04:05PM EST  Rezolute Announces Change of Transfer Agent   GlobeNewswire Inc
Dec 3, 2020
08:00AM EST  FDA Clears Rezolutes IND Application for RZ402   GlobeNewswire Inc
Nov 19, 2020
08:00AM EST  Rezolute to Present at the Piper Sandler 32nd Annual Virtual   GlobeNewswire Inc
Nov 13, 2020
04:06PM EST  Rezolute Files Prospectus Related To Offer & Sale, From Time To Time, Of Up To 3.3M Shares By Selling Stockholders   Benzinga
Nov 5, 2020
08:34AM EST  Rezolute Announces Uplisting To Nasdaq; Expected To Begin Trading Nov. 9 Under Symbol 'RZLT'   Benzinga
08:00AM EST  Rezolute Announces Uplisting to the Nasdaq Capital Market   GlobeNewswire Inc
Oct 14, 2020
07:11AM EDT  JMP Securities Maintains Market Outperform on REZOLUTE INC by Rezolute, Inc., Raises Price Target to $30   Benzinga
Oct 9, 2020
08:30AM EDT  Rezolute, Inc. (OCTQB:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic, and life-threatening diseases, announced today a $41 million private placement which is being led by CAM Capital with Federated Hermes Kaufmann, Surveyor Capital (a Citadel company) and BVF Partners participating, among others.   GlobeNewswire Inc
Sep 10, 2020
08:00AM EDT  Rezolute, Inc.(Rezolute or the Company) (OTCQB:RZLT), announced today that the Company has appointed veteran global healthcare executive Philippe Fauchet, O.B.E. to its board of directors.   GlobeNewswire Inc
Jul 27, 2020
08:00AM EDT  Rezolute, Inc. (Rezolute or the Company) (OTCQB:RZLT), today provided an update on the status of the Companys clinical programs in the context of the global COVID-19 pandemic (Pandemic), including its Phase 2b study for RZ358 (RIZE) in congenital hyperinsulinism (CHI) patients as well as a Phase 1 study for RZ402 in healthy volunteers.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC